NeoGenomics Statistics
Share Statistics
NeoGenomics has 25.74M
shares outstanding. The number of shares has increased by 0.59%
in one year.
| Shares Outstanding | 25.74M |
| Shares Change (YoY) | 0.59% |
| Shares Change (QoQ) | 0.08% |
| Owned by Institutions (%) | 96.83% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 640 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 4.98M, so 3.88% of the outstanding
shares have been sold short.
| Short Interest | 4.98M |
| Short % of Shares Out | 3.88% |
| Short % of Float | 5.38% |
| Short Ratio (days to cover) | 2.4 |
Valuation Ratios
The PE ratio is -5.3 and the forward
PE ratio is 22.9.
NeoGenomics's PEG ratio is
0.46.
| PE Ratio | -5.3 |
| Forward PE | 22.9 |
| PS Ratio | 0.63 |
| Forward PS | 0.2 |
| PB Ratio | 0.46 |
| P/FCF Ratio | -12.26 |
| PEG Ratio | 0.46 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for NeoGenomics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.98,
with a Debt / Equity ratio of 0.67.
| Current Ratio | 1.98 |
| Quick Ratio | 1.89 |
| Debt / Equity | 0.67 |
| Debt / EBITDA | -400.62 |
| Debt / FCF | -17.78 |
| Interest Coverage | -13.92 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $300,257.27 |
| Profits Per Employee | $-35,784.55 |
| Employee Count | 2,200 |
| Asset Turnover | 0.4 |
| Inventory Turnover | 13.85 |
Taxes
| Income Tax | -1.95M |
| Effective Tax Rate | 2.42% |
Stock Price Statistics
The stock price has increased by -47.55% in the
last 52 weeks. The beta is 1.6, so NeoGenomics's
price volatility has been higher than the market average.
| Beta | 1.6 |
| 52-Week Price Change | -47.55% |
| 50-Day Moving Average | 9.29 |
| 200-Day Moving Average | 13.84 |
| Relative Strength Index (RSI) | 43.98 |
| Average Volume (20 Days) | 2,072,649 |
Income Statement
In the last 12 months, NeoGenomics had revenue of 660.57M
and earned -78.73M
in profits. Earnings per share was -3.1.
| Revenue | 660.57M |
| Gross Profit | 290.1M |
| Operating Income | -92.11M |
| Net Income | -78.73M |
| EBITDA | -1.51M |
| EBIT | -74.06M |
| Earnings Per Share (EPS) | -3.1 |
Full Income StatementBalance Sheet
The company has 367.01M in cash and 605.33M in
debt, giving a net cash position of -238.32M.
| Cash & Cash Equivalents | 367.01M |
| Total Debt | 605.33M |
| Net Cash | -238.32M |
| Retained Earnings | -325.78M |
| Total Assets | 1.6B |
| Working Capital | 294.24M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 7.02M
and capital expenditures -41.06M, giving a free cash flow of -34.04M.
| Operating Cash Flow | 7.02M |
| Capital Expenditures | -41.06M |
| Free Cash Flow | -34.04M |
| FCF Per Share | -0.27 |
Full Cash Flow StatementMargins
Gross margin is 43.92%, with operating and profit margins of -13.94% and -11.92%.
| Gross Margin | 43.92% |
| Operating Margin | -13.94% |
| Pretax Margin | -12.21% |
| Profit Margin | -11.92% |
| EBITDA Margin | -0.23% |
| EBIT Margin | -13.94% |
| FCF Margin | -5.15% |
